Identifying Characteristics of Bone Marrow Failure Syndromes
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Bone marrow failure syndromes (BMFS) are rare disorders characterized by dysfunctional hematopoietic stem cells, which give rise to all red and white blood cells. The deficiency of blood cells, or cytopenia, caused by this malfunction leads to an assortment of diseases and disorders, all of which are characterized as BMFS. Because these diseases are rare, conducting research on them is difficult, and standards of treatment for most BMFS have yet to be developed. This study will collect clinical and laboratory data from people with BMFS to identify the characteristics and biological markers associated with these diseases over time. This information will assist doctors and researchers to develop better therapies and diagnostic tests that will help improve the management of BMFS and cytopenias.
| Condition |
|---|
|
Bone Marrow Failure Syndromes Anemia, Aplastic Myelodysplastic Syndromes Hemoglobinuria, Paroxysmal Red-Cell Aplasia, Pure Purpura, Thrombocytopenic Leukemia, Lymphocytic |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias |
Residual samples from peripheral blood and bone marrow aspiration/biopsies
| Estimated Enrollment: | 450 |
| Study Start Date: | April 2006 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
BMFS result from hematopoietic progenitor or stem cell failure within the bone marrow. Specific causes of this problem, however, have been difficult to identify, as BMFS occur sporadically. For the same reason, few studies have been conducted to find out more about these diseases and to develop more appropriate and effective therapies. Aplastic anemia (AA) is the most common of all BMFS. Other types of BMFS include the following: myelodysplastic syndrome (MDS); paroxysmal nocturnal hemoglobinuria (PNH); pure red cell aplasia (PRCA); amegakaryocytic thrombocytopenic purpura (ATP); and large granular lymphocyte leukemia (LGL leukemia). Though AA is the most common of the BMFS, all BMFS are closely related in terms of their symptoms and characteristics. This study will collect clinical and laboratory data from people with BMFS to identify the characteristics and biological markers specific to each disease as it evolves. This information will assist doctors and researchers to devise better therapies and diagnostic tests that will help improve the management of BMFS and cytopenias.
Participants in this observational study will report to the study site for an initial screening visit, followed by study visits every 6 months for at least 5 years. At each visit, participants will be interviewed and examined by a physician. Laboratory tests, including blood collection and a bone marrow aspirate, will also be performed. Data collected for this study's database will be used to determine the prevalence of clinical events and laboratory abnormalities over the course of disease, to study the evolution of disease parameters and symptoms, and to evaluate current therapies and diagnostic tests.
Eligibility| Ages Eligible for Study: | 11 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Individuals with bone marrow failure syndromes
Inclusion Criteria:
- Diagnosis of one of the following diseases: aplastic anemia; myelodysplastic syndrome; paroxysmal nocturnal hemoglobinuria; idiopathic pure red cell aplasia; amegakaryocytic thrombocytopenia purpura; or large granular lymphocyte leukemia
Exclusion Criteria:
- N/A
Contacts and Locations| United States, California | |
| University of California, Los Angeles, Department of Hematology and Oncology | |
| Los Angeles, California, United States, 90095 | |
| United States, Florida | |
| H. Lee Moffitt Cancer Center | |
| Tampa, Florida, United States, 33612 | |
| United States, Ohio | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| Pennsylvania State University Cancer Center | |
| Hershey, Pennsylvania, United States, 17033 | |
| Study Chair: | Jaroslaw P. Maciejewski, MD, PhD | The Cleveland Clinic |
More Information
Publications:
| Responsible Party: | Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic Foundation |
| ClinicalTrials.gov Identifier: | NCT00315419 History of Changes |
| Other Study ID Numbers: | RDCRN 5401, RR19397-03 |
| Study First Received: | April 14, 2006 |
| Last Updated: | April 19, 2010 |
| Health Authority: | United States: Federal Government |
Keywords provided by Office of Rare Diseases (ORD):
|
Large Granular Lymphocyte Leukemia Amegakaryocytic Thrombocytopenic Purpura Idiopathic Pure Red Cell Aplasia Paroxysmal Nocturnal Hemoglobinuria |
Additional relevant MeSH terms:
|
Anemia Anemia, Aplastic Hemoglobinuria Hemoglobinuria, Paroxysmal Leukemia Leukemia, Lymphoid Myelodysplastic Syndromes Preleukemia Pancytopenia Purpura Red-Cell Aplasia, Pure Purpura, Thrombocytopenic Hematologic Diseases Bone Marrow Diseases Proteinuria |
Urination Disorders Urologic Diseases Urological Manifestations Signs and Symptoms Anemia, Hemolytic Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Precancerous Conditions Blood Coagulation Disorders Hemorrhage Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013